Report
mdxhealth FIRST LOOK: 1H24 results continue impressive topline growth
In line with previously reported preliminary results, mdxhealth's 1H24 results feature a strong +32% y/y uptake in revenues, while cash burn gradually comes down. Management reiterates its recently upped $ 85-87m FY24 revenue guidance and it still foresees adjusted EBITDA profitability by 1H25. We see mdxhealth as a uniquely positioned player in the urology diagnostics space, and reiterate a $ 6.0 TP and Buy rating.
Underlying
MDXHEALTH
Provider
KBC Securities
We are a financial services provider for several types of professional clients, each with distinct needs.
Thomas Vranken
Other Reports on these Companies
Other Reports from KBC Securities
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.